News | Peripheral Artery Disease (PAD) | May 14, 2018

SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease

Online resource will provide patient-centered information on PAD risk factors, therapies and patient education

SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease

May 14, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and Treatment Resource Center. This center will be an ongoing, patient-centered quality improvement initiative focused on helping increase peripheral artery disease (PAD) awareness in the cardiovascular and internal medicine community by delving into the underlying risks of this disease state.

PAD impacts more than 10 million patients in the United States alone yet is woefully underdiagnosed. Lack of screening, underdiagnosis and undertreatment of PAD represent a critical gap in service to patients, as even asymptomatic PAD status is associated with the high long-term cardiovascular morbidity and mortality. Therefore, PAD has been targeted as one of SCAI’s key areas for quality improvement.

“I am excited to co-chair this important SCAI initiative on PAD awareness and education,” said Rajesh Swaminathan, M.D., FSCAI. “The condition is nearly as prevalent as CAD [coronary artery disease], yet still underdiagnosed. Early identification of PAD is key to proper counseling, risk factor modification and management to prevent future adverse clinical outcomes. The goal here is to provide PAD education, with incorporation of new clinical data in various formats, to inform and engage referring physicians, advanced practice providers, and fellows-in-training,” said Swaminathan.

The initiative also aims to improve the management and outcomes for PAD patients by providing a comprehensive review of “PAD 101.” This includes comprehensive discussions of:

  • Emerging data for secondary prevention in stable PAD;
  • Presentations to understand how to manage PAD patients; and
  • When to refer PAD patients for invasive therapies.

The multiyear program will be comprised of the following components:

  • The PAD Diagnosis and Treatment Resource Center: A five-part modular resource center hosted on SCAI’s website and packaged for easy download and dissemination; and
  • Webcast Series: A series of 30-minute webcasts based upon the PAD Diagnosis and Treatment Resource Center topics.

“The invasive therapy module will provide an evidence-based overview of the benefits of endovascular therapy and will help to clarify which patients should be considered for such therapy,” said Dmitriy Feldman, M.D., FSCAI, co-chair of the working group. “Furthermore, this module will focus on the SCAI-led Appropriate Use Criteria in EVT document as well as the newly released at SCAI 2018 Consensus Guidelines for Device Selection in Femoral-Popliteal Arterial Interventions.”

For more information: www.scai.org/padtoolkit

 

Related Content

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
Overlay Init